Sign in Subscribe
Genetic research

Breakthrough in Cancer Gene Therapy: Researchers Develop Protective Liposomes for Systemic Adenovirus Treatments

Strategic Insights

— 1 min read

Investigators at the University of California San Diego (UCSD) have made significant strides in cancer gene therapy, developing a novel liposome coating procedure that shields adenovirus-based treatments from pre-existing antibodies in human blood. This innovation could pave the way for more effective systemic adenovirus treatments for cancer.

Key Takeaways:

  • Researchers developed a liposome coating procedure that protects adenovirus (Ad) from neutralizing antibodies in human blood, allowing for systemic Ad treatments.
  • The novel liposome formulation provides 12-fold protection in vivo relative to unencapsulated Ads.
  • In vitro optimization of the liposome coating reveals a strong correlation between the structural stability of liposomes and protection against anti-Ad neutralizing antibodies.
  • The liposome-encapsulated Ad (DfAd) formulation shows promise for the systemic treatment of cancer, with the potential to overcome the limitations of previous Ad therapies.
  • The research identified DSPE-PEG2000-carboxylic acid (DSPE-PEG2000-CA) as a critical component for liposome stability and increasing protection against antibody neutralization of the encapsulated Ad.
  • The study's innovative in vivo assay for liposome protection against neutralizing antibodies and in vitro experiments provide new tools and insights for designing liposome-Ad complexes for cancer treatment.
  • The findings have significant implications for cancer gene therapy and could lead to the development of more effective and safer treatments.

Statistics:

  • 12-fold protection in vivo relative to unencapsulated Ads
  • 17(6):769 - the volume of the journal article "Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response" in Pharmaceutics
  • 2025 - the research was conducted and published
  • 100% (free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.3390/pharmaceutics17060769)

Sources:

  • "Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response." Pharmaceutics, 2025,17(6):769. (Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/)
  • NewsRx. Data on Cancer Gene Therapy Discussed by Researchers at University of California San Diego (UCSD) (Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response). Vaccine Weekly. July 9, 2025; p 11.

Read more